Syndax Pharmaceuticals (SNDX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$436.0 million.
- Syndax Pharmaceuticals' Enterprise Value fell 1190.23% to -$436.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$436.0 million, marking a year-over-year decrease of 1190.23%. This contributed to the annual value of -$572.9 million for FY2024, which is 38.3% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported Enterprise Value of -$436.0 million as of Q3 2025, which was down 1190.23% from -$455.2 million recorded in Q2 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Enterprise Value peaked at -$222.2 million during Q4 2021, and registered a low of -$572.9 million during Q4 2024.
- Over the past 5 years, Syndax Pharmaceuticals' median Enterprise Value value was -$398.8 million (recorded in 2023), while the average stood at -$397.2 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 17386.0% in 2021, then crashed by 38.3% in 2024.
- Over the past 5 years, Syndax Pharmaceuticals' Enterprise Value (Quarter) stood at -$222.2 million in 2021, then plummeted by 114.14% to -$475.8 million in 2022, then fell by 19.94% to -$570.7 million in 2023, then dropped by 0.38% to -$572.9 million in 2024, then rose by 23.9% to -$436.0 million in 2025.
- Its Enterprise Value stands at -$436.0 million for Q3 2025, versus -$455.2 million for Q2 2025 and -$512.2 million for Q1 2025.